{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T08:06:36Z","timestamp":1784707596258,"version":"3.55.0"},"reference-count":54,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Motor proteins play significant roles in cancer progression, but their involvement in biochemical recurrence (BCR) of prostate cancer remains unclear. The objective of the study is to develop a prognostic indicator for BCR using machine learning (ML) and motor protein-related genes (MPRGs).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>The prognosis relevance of the MPRGs in prostate cancer was analyzed by univariate Cox regression. Feature selection and model construction were performed using combinations of multiple machine learning algorithms. Model performance was assessed using receiver operating characteristic curve and C-index. Patients were stratified into high- and low-risk groups based on the risk signature, and comparisons of BCR incidence, gene expression profiles, immune cell infiltration patterns, and drug sensitivity were conducted between these groups. The gene expression of MPRGs were validated in vitro.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Among 120 MPRGs, 17 were differentially expressed, of which 8 were significantly associated with BCR. A novel risk scoring system using a StepCox[forward] + Ridge model based on these 8 MPRGs effectively stratified patients into two different risk groups, and patients with high riskscores had significantly higher BCR rates than those with lower riskscores. Enrichment analysis revealed upregulation of inflammation response, EMT, hypoxia, and estrogen response pathways in the high-risk category, while mitotic spindle, G2M checkpoint, and E2F targets were downregulated. The MPRG-derived risk score correlated positively with M2 macrophage infiltration and ngatively correlated with CD4 T cells and mast cells, and the high-risk category showed higher sensitivity to drugs like cisplatin and bicalutamide. The final nomogram based on MPRGs-derived signature and T stage provided an excellent tool for predicting BCR. In vitro experiments further validated that the expression trends of MPRGs in the risk signature were consistent with the bioinformatics analysis results.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>This study developed a novel MPRG-derived risk signature that effectively predicts BCR in prostate cancer, offering valuable insights for clinical management and personalized treatment strategies.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0332747","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T17:35:31Z","timestamp":1758044131000},"page":"e0332747","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Development of a prostate cancer biochemical recurrence risk signature using machine learning and motor protein-related genes"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9241-0504","authenticated-orcid":true,"given":"Weixing","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohai","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonggao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,9,16]]},"reference":[{"issue":"1","key":"pone.0332747.ref001","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"RL Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"pone.0332747.ref002","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/pros.20115","article-title":"Androgen deprivation therapy for prostate cancer: current status and future prospects","volume":"61","author":"H Miyamoto","year":"2004","journal-title":"Prostate"},{"issue":"1","key":"pone.0332747.ref003","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41391-018-0079-0","article-title":"Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations","volume":"22","author":"ED Crawford","year":"2019","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"pone.0332747.ref004","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9040339","article-title":"Novel strategies for treating castration-resistant prostate cancer","volume":"9","author":"DK Leung","year":"2021","journal-title":"Biomedicines"},{"issue":"4","key":"pone.0332747.ref005","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1001\/jama.294.4.433","article-title":"Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy","volume":"294","author":"SJ Freedland","year":"2005","journal-title":"JAMA"},{"issue":"12","key":"pone.0332747.ref006","doi-asserted-by":"crossref","first-page":"103436","DOI":"10.1016\/j.sjbs.2022.103436","article-title":"Role of motor proteins in human cancers","volume":"29","author":"I Hassan Ibrahim","year":"2022","journal-title":"Saudi J Biol Sci"},{"key":"pone.0332747.ref007","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10555-009-9185-8","article-title":"Kinesin motor proteins as targets for cancer therapy","volume":"28","author":"D Huszar","year":"2009","journal-title":"Cancer Metastasis Rev"},{"key":"pone.0332747.ref008","article-title":"Dynein-powered cell locomotion guides metastasis of breast cancer","author":"Y Tagay","year":"2023","journal-title":"bioRxiv"},{"issue":"5","key":"pone.0332747.ref009","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s12032-021-01494-x","article-title":"High KIFC1 expression is associated with poor prognosis in prostate cancer","volume":"38","author":"LG Kostecka","year":"2021","journal-title":"Med Oncol"},{"issue":"3","key":"pone.0332747.ref010","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3892\/ol.2022.13432","article-title":"KIF11: A potential prognostic biomarker for predicting bone metastasis-free survival of prostate cancer","volume":"24","author":"H Wang","year":"2022","journal-title":"Oncol Lett"},{"issue":"5","key":"pone.0332747.ref011","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1089\/omi.2011.0118","article-title":"clusterProfiler: an R package for comparing biological themes among gene clusters","volume":"16","author":"G Yu","year":"2012","journal-title":"OMICS"},{"key":"pone.0332747.ref012","doi-asserted-by":"crossref","first-page":"687975","DOI":"10.3389\/fimmu.2021.687975","article-title":"IOBR: multi-omics immuno-oncology biological research to decode tumor microenvironment and signatures","volume":"12","author":"D Zeng","year":"2021","journal-title":"Front Immunol"},{"issue":"9","key":"pone.0332747.ref013","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0107468","article-title":"pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels","volume":"9","author":"P Geeleher","year":"2014","journal-title":"PLoS One"},{"issue":"24","key":"pone.0332747.ref014","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2017.7248","article-title":"The diagnosis and treatment of prostate cancer: a review","volume":"317","author":"MS Litwin","year":"2017","journal-title":"JAMA"},{"issue":"11","key":"pone.0332747.ref015","doi-asserted-by":"crossref","first-page":"105253","DOI":"10.1016\/j.jbc.2023.105253","article-title":"The kinesin-14 family motor protein KIFC2 promotes prostate cancer progression by regulating p65","volume":"299","author":"X Liu","year":"2023","journal-title":"J Biol Chem"},{"key":"pone.0332747.ref016","doi-asserted-by":"crossref","first-page":"144989","DOI":"10.1016\/j.gene.2020.144989","article-title":"Inhibition of kinesin motor protein KIFC1 by AZ82 induces multipolar mitosis and apoptosis in prostate cancer cell","volume":"760","author":"A Parvin","year":"2020","journal-title":"Gene"},{"issue":"4","key":"pone.0332747.ref017","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.clgc.2016.10.005","article-title":"Kinesin family member 11 mRNA expression predicts prostate cancer aggressiveness","volume":"15","author":"XM Piao","year":"2017","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"pone.0332747.ref018","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12967-020-02323-x","article-title":"Development of an autophagy-related gene expression signature for prognosis prediction in prostate cancer patients","volume":"18","author":"D Hu","year":"2020","journal-title":"J Transl Med"},{"issue":"1","key":"pone.0332747.ref019","doi-asserted-by":"crossref","first-page":"1762473","DOI":"10.1080\/2162402X.2020.1762473","article-title":"A novel gene signature to predict immune infiltration and outcome in patients with prostate cancer","volume":"9","author":"N Shao","year":"2020","journal-title":"Oncoimmunology"},{"issue":"1","key":"pone.0332747.ref020","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2016.08.007","article-title":"KIFC1 induces resistance to docetaxel and is associated with survival of patients with prostate cancer","volume":"35","author":"Y Sekino","year":"2017","journal-title":"Urol Oncol"},{"issue":"2","key":"pone.0332747.ref021","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3390\/jcm8020225","article-title":"KIFC1 inhibitor CW069 induces apoptosis and reverses resistance to docetaxel in prostate cancer","volume":"8","author":"Y Sekino","year":"2019","journal-title":"J Clin Med"},{"issue":"1","key":"pone.0332747.ref022","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1186\/s12967-023-04760-w","article-title":"ND630 controls ACACA and lipid reprogramming in prostate cancer by regulating the expression of circKIF18B_003","volume":"21","author":"Y-P Wu","year":"2023","journal-title":"J Transl Med"},{"key":"pone.0332747.ref023","doi-asserted-by":"crossref","first-page":"9259","DOI":"10.2147\/CMAR.S272795","article-title":"Identification of G2 and S phase-expressed-1 as a potential biomarker in patients with prostate cancer","volume":"12","author":"J Xiong","year":"2020","journal-title":"Cancer Manag Res"},{"issue":"4","key":"pone.0332747.ref024","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/s41419-021-03582-2","article-title":"Kinesin family member 18B regulates the proliferation and invasion of human prostate cancer cells","volume":"12","author":"Y-P Wu","year":"2021","journal-title":"Cell Death Dis"},{"issue":"1","key":"pone.0332747.ref025","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13020-025-01086-1","article-title":"Atractylenolide I ameliorated the growth and enzalutamide resistance of castration-resistant prostate cancer by targeting KIF15","volume":"20","author":"C Han","year":"2025","journal-title":"Chin Med"},{"issue":"1","key":"pone.0332747.ref026","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41420-023-01625-5","article-title":"Knockdown of KIF15 suppresses proliferation of prostate cancer cells and induces apoptosis through PI3K\/Akt signaling pathway","volume":"9","author":"H Bi","year":"2023","journal-title":"Cell Death Discov"},{"key":"pone.0332747.ref027","doi-asserted-by":"crossref","first-page":"679173","DOI":"10.3389\/fonc.2021.679173","article-title":"KIF15 promotes progression of castration resistant prostate cancer by activating EGFR signaling pathway","volume":"11","author":"L Gao","year":"2021","journal-title":"Front Oncol"},{"key":"pone.0332747.ref028","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.bbrc.2021.08.072","article-title":"Kinesin 12 (KIF15) contributes to the development and tumorigenicity of prostate cancer","volume":"576","author":"Z Qureshi","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"pone.0332747.ref029","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1158\/0008-5472.CAN-20-1965","article-title":"KIF15-mediated stabilization of AR and AR-V7 contributes to enzalutamide resistance in prostate cancer","volume":"81","author":"L Gao","year":"2021","journal-title":"Cancer Res"},{"key":"pone.0332747.ref030","doi-asserted-by":"crossref","first-page":"109551","DOI":"10.1016\/j.abb.2023.109551","article-title":"KIF14 mediates cabazitaxel-docetaxel cross-resistance in advanced prostate cancer by promoting AKT phosphorylation","volume":"737","author":"L Liu","year":"2023","journal-title":"Arch Biochem Biophys"},{"issue":"28","key":"pone.0332747.ref031","doi-asserted-by":"crossref","first-page":"45459","DOI":"10.18632\/oncotarget.17564","article-title":"Overexpression of a novel candidate oncogene KIF14 correlates with tumor progression and poor prognosis in prostate cancer","volume":"8","author":"Y Zhang","year":"2017","journal-title":"Oncotarget"},{"issue":"20","key":"pone.0332747.ref032","doi-asserted-by":"crossref","first-page":"5479","DOI":"10.1158\/0008-5472.CAN-17-0496","article-title":"LSD1-mediated epigenetic reprogramming drives CENPE expression and prostate cancer progression","volume":"77","author":"Y Liang","year":"2017","journal-title":"Cancer Res"},{"issue":"6","key":"pone.0332747.ref033","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1016\/j.asjsur.2022.12.077","article-title":"Ferroptosis-related ACSL3 and ACTC1 predict metastasis-free survival for prostate cancer patients undergoing radical radiotherapy","volume":"46","author":"X Shi","year":"2023","journal-title":"Asian J Surg"},{"key":"pone.0332747.ref034","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jsbmb.2017.07.029","article-title":"Actin alpha cardiac muscle 1 gene expression is upregulated in the skeletal muscle of men undergoing androgen deprivation therapy for prostate cancer","volume":"174","author":"AS Cheung","year":"2017","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"6","key":"pone.0332747.ref035","article-title":"Novel insights in cell cycle dysregulation during prostate cancer progression","volume":"28","author":"S Ben-Salem","year":"2021","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"pone.0332747.ref036","first-page":"3085","article-title":"KRAS gene silencing inhibits the activation of PI3K-Akt-mTOR signaling pathway to regulate breast cancer cell epithelial-mesenchymal transition, proliferation and apoptosis","volume":"24","author":"Y Zhang","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"21","key":"pone.0332747.ref037","doi-asserted-by":"crossref","first-page":"35376","DOI":"10.18632\/oncotarget.15686","article-title":"Epithelial-mesenchymal transition in prostate cancer: an overview","volume":"8","author":"M Montanari","year":"2017","journal-title":"Oncotarget"},{"issue":"16","key":"pone.0332747.ref038","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21165611","article-title":"Hypoxia and HIF signaling: one axis with divergent effects","volume":"21","author":"C Corrado","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"1","key":"pone.0332747.ref039","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","article-title":"Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions","volume":"8","author":"Z Chen","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"pone.0332747.ref040","doi-asserted-by":"crossref","first-page":"4972","DOI":"10.1038\/s41467-018-07411-7","article-title":"Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen\/AR-targeted therapy","volume":"9","author":"H Geng","year":"2018","journal-title":"Nat Commun"},{"key":"pone.0332747.ref041","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.semcancer.2023.11.006","article-title":"Tumor hypoxia and radiotherapy: A major driver of resistance even for novel radiotherapy modalities","volume":"98","author":"C Beckers","year":"2024","journal-title":"Semin Cancer Biol"},{"key":"pone.0332747.ref042","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/978-3-030-12734-3_9","article-title":"Hypoxia-induced resistance to chemotherapy in cancer","volume":"1136","author":"LM Minassian","year":"2019","journal-title":"Adv Exp Med Biol"},{"issue":"10","key":"pone.0332747.ref043","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12102984","article-title":"Inflammation as a driver of prostate cancer metastasis and therapeutic resistance","volume":"12","author":"M Archer","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"7","key":"pone.0332747.ref044","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s00018-010-0600-7","article-title":"Role of xenobiotic metabolism in cancer: involvement of transcriptional and miRNA regulation of P450s","volume":"68","author":"V Tam\u00e1si","year":"2011","journal-title":"Cell Mol Life Sci"},{"key":"pone.0332747.ref045","doi-asserted-by":"crossref","first-page":"165530","DOI":"10.1016\/j.scitotenv.2023.165530","article-title":"Genetic variants of antioxidant and xenobiotic metabolizing enzymes and their association with prostate cancer: a meta-analysis and functional in silico analysis","volume":"898","author":"B \u00c1lvarez-Gonz\u00e1lez","year":"2023","journal-title":"Sci Total Environ"},{"issue":"5","key":"pone.0332747.ref046","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/ncb2958","article-title":"Mitotic spindle multipolarity without centrosome amplification","volume":"16","author":"H Maiato","year":"2014","journal-title":"Nat Cell Biol"},{"issue":"1","key":"pone.0332747.ref047","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.semcancer.2004.09.003","article-title":"Centrosomal amplification and spindle multipolarity in cancer cells","volume":"15","author":"W Saunders","year":"2005","journal-title":"Semin Cancer Biol"},{"key":"pone.0332747.ref048","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2015.11.002","article-title":"Mitotic catastrophe and cancer drug resistance: a link that must to be broken","volume":"24","author":"TV Denisenko","year":"2016","journal-title":"Drug Resist Updat"},{"issue":"1","key":"pone.0332747.ref049","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s12967-024-06051-4","article-title":"G2M-checkpoint related immune barrier structure and signature for prognosis and immunotherapy response in hepatocellular carcinoma: insights from spatial transcriptome and machine learning","volume":"23","author":"X Chen","year":"2025","journal-title":"J Transl Med"},{"issue":"5","key":"pone.0332747.ref050","doi-asserted-by":"crossref","first-page":"150923","DOI":"10.1016\/j.soncn.2019.08.002","article-title":"Cancer and the immune system: the history and background of immunotherapy","volume":"35","author":"M Abbott","year":"2019","journal-title":"Semin Oncol Nurs"},{"issue":"4","key":"pone.0332747.ref051","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2020.08.007","article-title":"Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the checkmate 650 trial","volume":"38","author":"P Sharma","year":"2020","journal-title":"Cancer Cell"},{"issue":"3","key":"pone.0332747.ref052","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41391-021-00340-5","article-title":"How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer","volume":"24","author":"J Stultz","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"pone.0332747.ref053","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12943-022-01630-9","article-title":"CircSMARCC1 facilitates tumor progression by disrupting the crosstalk between prostate cancer cells and tumor-associated macrophages via miR-1322\/CCL20\/CCR6 signaling","volume":"21","author":"T Xie","year":"2022","journal-title":"Mol Cancer"},{"issue":"4","key":"pone.0332747.ref054","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1001\/jamaoncol.2021.7298","article-title":"Efficacy and safety of autologous dendritic cell-based immunotherapy, docetaxel, and prednisone vs placebo in patients with metastatic castration-resistant prostate cancer: the VIABLE Phase 3 randomized clinical trial","volume":"8","author":"NJ Vogelzang","year":"2022","journal-title":"JAMA Oncol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0332747","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T17:35:53Z","timestamp":1758044153000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0332747"}},"subtitle":[],"editor":[{"given":"Elnaz","family":"Pashaei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,9,16]]},"references-count":54,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0332747","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,16]]}}}